Clinical question: When performing guided bone regeneration (GBR) alongside immediate implant placement in the posterior mandible, which barrier membrane works better — an autogenous dentine-derived barrier membrane (DDBM) or an extended, albumin-enriched platelet-rich fibrin (e-PRF)? This 2-year randomized controlled trial put two biological, patient-derived materials head to head.

Methodology: Forty patients with non-restorable mandibular molars indicated for immediate implant placement and GBR were randomized into two equal groups of 20. Group 1 received a demineralized DDBM — type I collagen derived from the patient's own extracted tooth. Group 2 received e-PRF (also called Alb-PRF), a fibrin membrane engineered to extend its functional life to 4-6 months. Patients were assessed immediately and at 3, 6, 12 and 24 months for implant stability, peri-implant probing depth (PPD), marginal bone loss (MBL) and relative bone density.

Main findings: Both materials performed well, and they performed similarly. Implant survival was 100% across both groups over 24 months. Implant stability rose significantly over time in both arms, with no meaningful difference between them (at 12 months, median stability ~78-79). PPD increased modestly but stayed within healthy limits — around 3.25 mm at 24 months in both groups. MBL increased over time but remained low and statistically comparable: buccal MBL ~1.22 mm (DDBM) vs ~1.30 mm (e-PRF), lingual ~1.27 mm in both. Relative bone density rose significantly within each group with no intergroup difference. In short, no clinical or radiographic parameter separated the two membranes at two years.

Clinical relevance: The practical message is one of options. For GBR with immediate implants in the posterior mandible, both an autogenous dentine membrane and extended PRF deliver stable, healthy peri-implant tissues over two years — and both are biological, cost-effective alternatives to commercial membranes. The choice can therefore hinge on logistics rather than outcome. DDBM repurposes the very tooth being extracted, elegant when an extraction is already part of the plan. e-PRF is autologous, chairside, and avoids reliance on a suitable donor tooth. Neither carries the cost of a xenogeneic or synthetic membrane. Two caveats: the sample is modest (40 patients) and the indication is specific (posterior mandible, immediate placement), so the equivalence should not be over-generalized to vertical augmentation or esthetic zones. Still, for the implantologist who values biological, low-cost solutions, this trial widens the toolkit without forcing a trade-off in results.